Načítá se...
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL)1. While a majority of patients will achieve a complete response following a single infusion of CD19 CAR T cells(2–4), the broad applicabi...
Uloženo v:
| Vydáno v: | Nat Med |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6410714/ https://ncbi.nlm.nih.gov/pubmed/29808005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0041-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|